Successfully applied drugs targeting BCR‐ABL1 fusion in hematological malignancy ALK fusion in NSCLC, have dramatically ignited enthusiasm for deep exploration of the landscape of gene fusions (Mertens et al., 2015). This evidence concerns the gene ABL1 and non-small cell lung carcinoma.